Japan's SBI Group To Buy 40% Of China's Suzhou Yian Biotech
This article was originally published in PharmAsia News
Executive Summary
SBI Group, a Japanese financial services company, says it plans to acquire 40% of Suzhou Yian Biotech, a Chinese bioventure.